JP6377070B2 - ペプチド化合物及びその製造方法及びその使用 - Google Patents

ペプチド化合物及びその製造方法及びその使用 Download PDF

Info

Publication number
JP6377070B2
JP6377070B2 JP2015546558A JP2015546558A JP6377070B2 JP 6377070 B2 JP6377070 B2 JP 6377070B2 JP 2015546558 A JP2015546558 A JP 2015546558A JP 2015546558 A JP2015546558 A JP 2015546558A JP 6377070 B2 JP6377070 B2 JP 6377070B2
Authority
JP
Japan
Prior art keywords
peptide
seq
wound
cap37
arginine residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015546558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501889A5 (cg-RX-API-DMAC7.html
JP2016501889A (ja
Inventor
ペレイラ,エイチ.,アン
カサス—ヤコビ,アン
カサス―ヤコビ,アン
グリフィス,ジーナ,エル.
Original Assignee
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ, ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ filed Critical ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ
Publication of JP2016501889A publication Critical patent/JP2016501889A/ja
Publication of JP2016501889A5 publication Critical patent/JP2016501889A5/ja
Application granted granted Critical
Publication of JP6377070B2 publication Critical patent/JP6377070B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015546558A 2012-12-03 2013-12-03 ペプチド化合物及びその製造方法及びその使用 Active JP6377070B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261732750P 2012-12-03 2012-12-03
US61/732,750 2012-12-03
US201361812584P 2013-04-16 2013-04-16
US61/812,584 2013-04-16
US201361813527P 2013-04-18 2013-04-18
US61/813,527 2013-04-18
PCT/US2013/072884 WO2014089088A1 (en) 2012-12-03 2013-12-03 Peptide compounds and methods of production and use thereof

Publications (3)

Publication Number Publication Date
JP2016501889A JP2016501889A (ja) 2016-01-21
JP2016501889A5 JP2016501889A5 (cg-RX-API-DMAC7.html) 2018-05-10
JP6377070B2 true JP6377070B2 (ja) 2018-08-22

Family

ID=50883940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015546558A Active JP6377070B2 (ja) 2012-12-03 2013-12-03 ペプチド化合物及びその製造方法及びその使用

Country Status (7)

Country Link
US (2) US9603896B2 (cg-RX-API-DMAC7.html)
EP (1) EP2925341B1 (cg-RX-API-DMAC7.html)
JP (1) JP6377070B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013355391B2 (cg-RX-API-DMAC7.html)
CA (1) CA2893504C (cg-RX-API-DMAC7.html)
DK (1) DK2925341T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014089088A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
JP6405365B2 (ja) 2013-04-16 2018-10-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ ペプチド化合物及びその製造方法及びその使用
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
CN106397456B (zh) * 2016-08-31 2019-05-07 成都倍特药业有限公司 一种含高纯度头孢地尼的组合物及其精制方法
EP3802568A4 (en) 2018-06-08 2022-07-13 The Board of Regents of the University of Oklahoma PEPTIDE THERAPEUTICS USED TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES
CN117586376A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效胰岛素化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6107460A (en) 1999-03-01 2000-08-22 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use thereof
WO2002042259A2 (en) * 2000-11-27 2002-05-30 University Of Maryland, Baltimore Methods of synthesizing and using derivatives of [2-(2-aminoethoxy)ethoxy] acetic acid
AU2002305845B2 (en) * 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
US7655480B2 (en) 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
US8450071B2 (en) 2002-03-08 2013-05-28 The Board Of Regents Of The University Of Oklahoma Biomarker and method for detecting a chronic inflammatory-associated disease
AU2003220034A1 (en) 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
US7354900B2 (en) * 2002-05-03 2008-04-08 The Board Of Regents Of The University Of Oklahoma Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
CN101300022A (zh) 2005-08-01 2008-11-05 俄克拉荷马州大学评议会 抗真菌肽和其使用方法
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
WO2011103567A2 (en) 2010-02-22 2011-08-25 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Peptides and methods for inducing cell death
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same

Also Published As

Publication number Publication date
US9603896B2 (en) 2017-03-28
CA2893504A1 (en) 2014-06-12
AU2013355391B2 (en) 2017-08-03
WO2014089088A1 (en) 2014-06-12
DK2925341T3 (en) 2018-05-07
EP2925341B1 (en) 2018-01-31
EP2925341A4 (en) 2016-10-05
US20150374785A1 (en) 2015-12-31
CA2893504C (en) 2016-11-22
AU2013355391A1 (en) 2015-07-23
EP2925341A1 (en) 2015-10-07
US20160317617A1 (en) 2016-11-03
JP2016501889A (ja) 2016-01-21

Similar Documents

Publication Publication Date Title
US20160317617A1 (en) Peptide Compounds and Methods of Production and Use Thereof
EP3233902B1 (en) Antifibrotic activity of gas6 inhibitor
JP2018527306A (ja) 安定化抗微生物性ペプチド
US9862748B2 (en) Peptide compounds and methods of production and use thereof
JP2023507201A (ja) トロンビン由来ペプチドを含む組成物およびその使用
JP5691049B2 (ja) 血管新生誘導活性及び抗菌活性を有する新規ポリペプチド並びにその医薬用途
JP2016501889A5 (cg-RX-API-DMAC7.html)
JPWO2010137594A1 (ja) 血管新生誘導活性及び抗菌活性を有するポリペプチドおよびそれを含有する創傷治療剤
JP6405365B2 (ja) ペプチド化合物及びその製造方法及びその使用
JPWO2008096816A1 (ja) 血管新生誘導剤及びそれに用いられるポリペプチド
US11884710B2 (en) Peptide compounds and methods of use in wound healing
JP6042106B2 (ja) メチオニン・スルホキシドを含む新規ポリペプチド
Zhang et al. Repolarization of inflammation-associated macrophages by multifunctional dual drug-loaded liposome with antibacterial capacity for acute lung sepsis synergistic therapy
HK1254810A1 (zh) 作為輻射緩和劑和輻射防護劑的bpi和其同源物的用途
HK1244825B (en) Antifibrotic activity of gas6 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180123

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180724

R150 Certificate of patent or registration of utility model

Ref document number: 6377070

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250